Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sangamo Biosciences ( (SGMO) ) has issued an update.
On June 12, 2025, Sangamo Therapeutics, Inc. held its annual meeting where stockholders approved significant amendments to the 2018 Equity Incentive Plan. This included increasing the number of shares available for issuance and the number of shares for incentive stock options. The meeting also saw the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the company’s independent auditor. These decisions reflect Sangamo’s strategic focus on expanding its equity incentives to attract and retain talent, which could enhance its competitive position in the biotech industry.
The most recent analyst rating on (SGMO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
Sangamo Biosciences faces substantial financial instability characterized by declining revenues and profitability, a strained balance sheet, and negative cash flows. Despite some positive developments in clinical programs and collaborations, the company’s immediate financial challenges and dependency on partnerships for sustainability weigh heavily on its overall score. Technical indicators further reinforce a bearish outlook.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Average Trading Volume: 7,006,295
Technical Sentiment Signal: Sell
Current Market Cap: $120.5M
For detailed information about SGMO stock, go to TipRanks’ Stock Analysis page.